Phase 1 – In silico Design (0–12 months)

Focused on computational design of antiviral candidates using AI and bioinformatics. No lab or virus handling is involved.

• Key roles: AI Engineer, Bioinformatician, Project Coordinator, Scientific Guarantor
• Outputs: 50–100 virtual molecules, AI model, molecular screening platform, Phase 2 grant application

Phase 2 – In vitro Testing (6–12 months)

Selected molecules are synthesized and tested on cell cultures for efficacy and toxicity.

• Additional role: Medicinal Chemist / Lab Specialist
• Outputs: 1–3 validated antiviral candidates

Phase 3 – In vivo Testing (12–24 months)

Promising compounds tested on animals to verify safety and efficacy. Conducted in certified BSL-3 labs.

• Additional role: Virologist (may be international, connected to partner facility)
• Output: One lead molecule for further development or licensing

Note:

If results are not promising, the platform can pivot to target other viruses using the same AI-based approach.